| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Article |


From The William Harvey Research Institute,*
London, United Kingdom; the Department of Human Anatomy and
Genetics,
University of Oxford, Oxford,
United Kingdom; and the Department of Biology,
Instituto de Biociências, Letras e Ciências
ExatasUniversidade Estadual Paulista, São Paulo, Brazil
| Abstract |
|---|
|
|
|---|
50%) of ANX-A1 on the plasma membrane of
intravascular neutrophils was intact. Extravasation into the
subendothelial matrix caused loss of this pool of intact protein (to
6%), concomitant with an increase in total amount of the
protein; only
25% of the total protein was now recognized by the
antibody raised against the N-terminus (ie, it was intact). In
the cytoplasm of these cells, ANX-A1 was predominantly
associated with large vacuoles, possibly endosomes. In
situ hybridization confirmed de novo synthesis
of ANX-A1 in the extravasated cells. In conclusion, biochemical
pathways leading to the externalization, proteolysis,
and synthesis of ANX-A1 are activated during the process of neutrophil
extravasation.
| Introduction |
|---|
|
|
|---|
The events that promote the interaction between a circulating neutrophil and the endothelium of an inflamed microvascular beds have recently been dissected. Classes of adhesion molecules and chemoattractants able to initiate and sustain the leukocyte migration process have been identified, attributing to each of them specific functions in the phenomena of cell rolling, adhesion, and emigration.3 Besides these pro-inflammatory mediators that have the function to attract the leukocyte out of the vessel into and toward the site of injury, other regulatory mechanisms must operate. For instance, a fraction of rolling leukocytes will actually become firmly adherent on the endothelium.4 Similarly, a relevant proportion of adherent cells that are apparently ready to begin the emigration or diapedesis process, actually detach from the endothelium and return to the blood flow.5,6 Therefore, endogenous regulatory mediators able to counteract the action of the pro-inflammatory mediators briefly mentioned above exist and operate at different phases of the leukocyte extravasation process.7
Annexin 1 (ANX-A1) is a 37-kd member of the annexin superfamily of proteins that share the likely irrelevant function to bind phospholipids in the presence of calcium ions.8 The N-terminal region of these proteins is unique to each member of the family, and it is likely to confer the specific activity that each annexin must play in cell pathophysiology. ANX-A1 is particularly abundant in neutrophils where it represents up to 4% of the cytosolic proteins.9,10 This finding may be of pathological importance, because the large majority of ANX-A1 detected in inflamed tissues is associated with the presence of this cell type.11,12
In a previous study we demonstrated that ANX-A1 is externalized onto the cell surface of neutrophils on adhesion to monolayers of endothelial cells in vitro.7 Once on the plasma membrane, the protein is likely to be cleaved at the N-terminus to obtain the 33-kd isoform, and therefore released into the extracellular milieu.7 In accordance with this model, ANX-A1 recovered from the bronchoalveolar lavage fluid of patients suffering from several forms of lung diseases, including cystic fibrosis, is predominantly of the 33-kd isoform, being cleaved between Val-36 and Ser-37.13,14 This catabolic feature significantly correlated with the presence of serine proteases,14 long known to be able to cleave the protein N-terminal region in different sites.15 The function of ANX-A1 externalized on the plasma membrane of adherent neutrophils is to down-regulate their emigration through the endothelial cells. Several laboratories, including our own, have demonstrated the antimigratory action of exogenous and, more importantly, endogenous ANX-A1, in vitro16 and in vivo studies, both in acute6,17,18 and chronic19 models of inflammation. Based on all this experimental evidence we proposed ANX-A1 as an autocrine inhibitor of the process of neutrophil extravasation.7 In this respect ANX-A1 groups with a series of endogenous anti-inflammatory agonists. Adenosine20 and lipoxin A421 generated in the microenvironment of a leukocyte adherent to the postcapillary endothelium act to reduce the degree of cell extravasation.
Despite this wealth of pharmacological data, very few in vitro studies have investigated the subcellular localization of ANX-A1 in resting or activated neutrophils. During the process of phagocytosis of the U937 monocytic cell line, ANX-A1 localizes around the phagosome, as demonstrated by immunocytochemical analysis.22 However this redistribution of the protein is stimulus-dependent, and it occurs when these cells phagocytose Escherichia coli but not Brucella suis.22 It is also cell-specific because it does not occur in neutrophils phagocytosing an attenuated strain of Mycobacterium tuberculosis23 or opsonized zymosan.24 In the latter in vitro study, we have been able to determine a high degree of co-localization between ANX-A1 and gelatinase in the matrix of cytosolic granules of human resting neutrophils. Therefore, increased ANX-A1 levels onto the plasma membrane of adherent neutrophils is consequent to a process of exocytosis.24,25
So far, no studies have monitored ANX-A1 distribution in migrating leukocytes by immunocytochemistry during an on-going inflammatory reaction in vivo. We have analyzed here the neutrophils, and assessed the subcellular localization of ANX-A1 in neutrophils adherent to the postcapillary venule endothelium as well as in cells already extravasated into the tissue. Intact (37 kd) ANX-A1 is predominantly found on the membrane of intravascular adherent neutrophils in vivo. Once in the extravascular tissue, the majority of the protein contained in the neutrophil is cleaved (33 kd isoform). Contact with extravascular matrix up-regulates ANX-A1 synthesis as determined by in situ hybridization analysis.
| Materials and Methods |
|---|
|
|
|---|
Male Sprague-Dawley rats (200 to 250 g body weight; Banton and Kingsman, Hull, UK) maintained on a standard chow pellet diet with tap water ad libitum were used for all experiments. Animals were housed at four animals per cage in a room with controlled lighting (lights on 8:00 to 20:00 hours) in which the temperature was maintained at 21 to 23°C, and the rats used 2 to 3 days after arrival. Animal work was performed according to Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act 1986).
Model of Inflammation
For pharmacological treatment, rats were administered human recombinant ANX-A1 (a generous gift of Dr. E. Solito, Inserm U332, Paris, France)26 intravenously at doses of 20 or 100 µg/kg27 in phosphate-buffered saline (PBS), or with 100 µl PBS alone. It must be noted that >90% sequence homology exists between human and rat ANX-A1 species.28 Five minutes later, experimental peritonitis was induced by the intraperitoneal injection of 1.5 mg/kg of carrageenin (type lambda; Sigma Chemical Co., Poole, Dorset, UK) in PBS. In all cases rats were sacrificed 4 hours later by CO2 exposure, this time-point being chosen because of the intense neutrophilic infiltrate produced in response to local injection of carra-geenin.29
Neutrophil migration was assessed both into the extravascular tissue and into the peritoneal cavity. Cavities were washed with 2 ml of PBS containing 25 U/ml heparin. Aliquots of the lavage fluids were stained with Turks solution (0.01% crystal violet in 3% acetic acid). Fragments of rat mesenteries (flat-mount preparations)30 fixed in 2% paraformaldehyde and 2% glutaraldehyde were stained with toluidine blue solution (1% toluidine blue in 1% borax solution). Differential cell counts were performed using a Neubauer hemocytometer and light microscopy (Olympus B061). The extent of neutrophil infiltration into the mesenteric tissues was then quantified by an observer unaware of the treatments as described below.
Western Blot Analysis
Mesenteries were dissected and immediately frozen in liquid N2, and homogenized at 4°C in 50 mmol/L Tris buffer rich in protease inhibitors (1 mmol/L phenylmethyl sulfonyl fluoride, 1.5 mmol/L pepstatin A, and 0.2 mmol/L leupeptin, pH 7.4) and centrifuged (4,000 x g, 5 minutes, 4°C). Protein concentrations in supernatants were determined by the Bradford assay (Sigma) and adjusted to 2 mg/ml, mixed 1:1 with 2x loading buffer (125 mmol/L Tris base, 2 mmol/L ethylenediaminetetraacetic acid, 10% mercaptoethanol, 4% sodium dodecyl sulfate, 20% glycerol, and 0.1% Coomassie blue, pH 6.8), and boiled for 5 minutes. Samples (20 µg proteins per lane), molecular weight markers, and standard ANX-A1 (10 to 1,000 ng) were resolved by gel electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels and transferred onto nitrocellulose membranes. ANX-A1 was detected using a specific monoclonal antibody raised against the entire protein.31 The signal was amplified with horseradish peroxidase-linked rat anti-mouse secondary antibody (1:3,000; Serotec, Oxford, UK) and visualized on BioMax MR-1 film (Kodak, Rochester, NY) after the application of Luminol (ECL; Amersham, Little Chalfont, UK). Densitometric analysis of the data produced a standard curve, and unknowns were quantified by interpolation.
Fixation, Processing, and Embedding for Immunofluorescence and Electron Microscopy
Animals were anesthetized by injection with sodium pentobarbital
(50 mg/kg) and perfused through the heart left ventricle with sterile
saline (30 to 50 ml per rat) for 30 to 60 seconds. This was followed by
a slow infusion of 100 ml of cold paraformaldehyde (2% in PBS) lasting
for 5 to 10 minutes. After perfusion, fragments of the mesentery were
postfixed in 4% paraformaldehyde and 0.5% glutaraldehyde, 0.1%
sodium cacodylate buffer (pH 7.4) for 24 hours at 4°C. They were then
washed in sodium cacodylate, dehydrated through a graded series of
ethanol, and embedded in LR Gold (London Resin Co., Reading, Berkshire,
UK). Sections (0.5 µm) were prepared for immunofluorescence and
stored at -70°C. For electron microscopy,
90-nm sections were cut
on an ultramicrotome (Reichert Ultracut; Leica, Austria) and placed on
nickel grids for immunogold labeling.
Fluorescence Immunohistochemistry
Sections (0.5-µm thick) were incubated for 1 hour with 10% sodium periodate (Sigma), then washed three times in 10 mmol/L PBS (pH 7.3) for 15 minutes. Fragments of the mesentery were permeabilized by 15 minutes incubation in 0.2% Triton X-100 in PBS (repeated three times). Nonspecific binding sites were blocked with normal rabbit serum in 0.1% bovine serum albumin in PBS. Sections were incubated overnight at 4°C with the primary antibody. Sections were then washed in PBS (15 minutes) and incubated with the secondary antibody, a fluorescein isothiocyanate-conjugated rabbit IgG anti-sheep IgG (Sigma), diluted 1:50, for 1 hour at room temperature. A final wash again in PBS (15 minutes) preceded mounting in Citifluor (Stanstead, Essex, UK).
Two distinct anti-ANX-A1 antibodies were used. A polyclonal sheep anti-ANX-A1 serum termed LCS3 raised against full-length human ANX-A1, and successfully used to detect the protein in rat systems,32 by both immunofluorescence and immunocytochemical techniques.24,33 A sheep anti-ANX-A1 serum termed LCPS1 raised against the unique N-terminal region of human ANX-A1 (peptide Ac2-26, Ac-AMVSEFLKQAWFIENEEQEYVQTVK),8 previously used to measure the levels of intact protein (37-kd isoform) in murine cells34 and human neutrophils24 was also used. Both LCS3 and LCPS1 have successfully been used to monitor ANX-A1 expression in rat mesenteric mast cells by electron microscopy,35 and have been shown to neutralize the activities of rat ANX-A1.36,37 Final dilution was 1:2,000 for both antisera.
As controls for the reaction, sections were incubated with nonimmune sheep serum (NSS; Sigma) instead of the primary antibody, at the same working dilution of 1:2,000. Another negative control was produced by pre-adsorbing LCS3 with 100 ng of ANX-A1 or LCPS1 with 10 µg of peptide Ac2-26. Sections were examined at a wavelength of 435 nm in an Olympus model BH2-RFCA model fluorescence microscope.
Postembedding Immunogold Labeling
To detect ANX-A1 in the tissues, a recently established immunogold staining procedure was used.35 Sections of the mesenteric tissues were prepared for electron microscopy by standard methods. Briefly, mesentery was stained with uranyl acetate (2% w/v in distilled water), dehydrated through increasing concentrations of ethanol (70 to 100%), and embedded in LR Gold resin. Ultrathin sections (0.2 µm) were incubated with the following reagents at room temperature: 1) 0.1 mol/L PBS containing 0.1% egg albumin (PBEA); 2) 2.5% normal rabbit serum in PBEA for 1 hour; 3) the sera LCS3, LCPS1, or nonimmune sheep serum (final dilutions of 1:300 in PBEA); 4) after five washes (3 minutes each) in PBEA, with a donkey anti-sheep IgG (Fc fragment-specific) antibody (Ab) (1:50 in PBEA) conjugated to 15-nm colloidal gold (British Biocell, Cardiff, UK). After 1 hour at 4°C, sections were extensively washed in PBEA and then in distilled water. Ultrathin sections were stained with uranyl acetate and lead citrate before examination on a Jeol 1200 EX II electron microscope.
In analogy to our study with human neutrophils in vitro,24 selected sections were double-labeled with LCPS1 and with an anti-human gelatinase rabbit serum (generous gift of Dr. N. Borregaard, Copenhagen, Denmark). Antibodies were used at a final dilution of 1:200. LCPS1-mediated immunoreactivity was detected with a donkey anti-sheep IgG (Fc fragment-specific) Ab (1:50 in PBEA) conjugated to 5-nm colloidal gold (British Biocell), whereas the anti-gelatinase staining was detected with a goat anti-rabbit IgG (Fc fragment-specific) Ab (1:50 in PBEA) conjugated to 15-nm colloidal gold (British Biocell).
Nonradioactive in Situ Hybridization with Oligonucleotide Probes
Animals were perfused as described above. Flat-mount preparations of the mesenteries were processed for in situ hybridization. The fragments were postfixed in 4% paraformaldehyde and 0.5% glutaraldehyde, 0.1 mol/L sodium cacodylate buffer, pH 7.4, for 2 hours at 4°C. After fixation, the sections were mounted on Superfrost (BDH, Poole, UK) slides. Hybridization histochemistry was performed according to a published method.35,38 The oligonucleotide probes were synthesized and purified commercially (Genosys, Poole, UK) and were directed against the N-terminal domain of LC1. Antisense probe: 5' GCA GGC CTG CTT GAG GAA TTC TGA TAC CAT TGC C3'. Sense probe: 5' CGT CCG GAC GAA CTC CTT AAG ACT ATG GTA ACG G3'. Oligonucleotides were labeled by tailing the 3' end with terminal transferase (Roche, Lewes, UK) and digoxigenin 11-dUTP (Roche). Oligonucleotide probes were checked against the GenBank database to eliminate sequences preventing obvious homologies with other known probes. Sections were washed with PBS, followed by treatment with 0.3% Triton X-100 in PBS (30 minutes) at room temperature. Sections were then incubated in prehybridization buffer (4x sodium chloride/sodium citrate, 1x Denhardts solution, 10 µg/ml denatured yeast tRNA, 1 µg/ml denatured salmon sperm DNA) at 37°C for 2 hours before incubation with labeled oligonucleotides (20 to 40 nmol/L) in hybridization buffer (50% formamide, 80 mmol/L Tris-HCl, pH 7.6, 10 µg/ml tRNA, 600 mmol/L NaCl, 0.1% sodium dodecyl sulfate, and 4 mmol/L EDTA) at 37°C, overnight.
After hybridization, sections were washed in 2x standard saline citrate and then placed in 0.1% standard saline citrate at room temperature. After washes in 0.1 mol/L Tris buffer for 20 minutes, slides were soaked in blocking solution (100 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1% bovine serum albumin) for 30 minutes at room temperature, before immersion in anti-digoxigenin alkaline phosphatase conjugate (Roche, UK) diluted 1:500 in blocking buffer for 2 hours at room temperature. Finally, slides were washed in buffer A (0.1 mol/L Tris-HCl, 1 mol/L NaCl, 2 mmol/L MgCl2, 1% bovine serum albumin, 0.1% Triton X-100) for 10 minutes and then with detection buffer (100 mmol/L Tris, pH 9.5, 100 mmol/L NaCl, 50 mmol/L MgCl2). They were reacted in a detection solution containing 360 mg/ml nitro blue tetrazolium and 140 mg/ml 5-bromo-6-chloro-3-indolyl phosphate p-toluidine salt (Roche, UK) for 48 hours at room temperature. The sections were mounted and coverslipped with Glycergel media (Sigma). Then, the same sections were stained with propidium iodide (Sigma) and were examined in a fluorescence microscope, using interference filters at two excitation wavelengths of 334 to 365 and 546 nm (Olympus model BH2-RFC).
Data Handling and Statistical Analysis
Cell extravasation data are reported as mean ± SE of four rats per group. Analysis of leukocyte infiltration in the mesenteric connective tissue was performed with a high-power objective (x40) counting neutrophils in 100-µm2 areas (analyzing at least 10 distinct determinations per sample). Similarly, randomly photographed sections of rat tissues were used for the immunocytochemical analysis. The area of each cell compartment (membrane, cytosol, and nucleus) for intravascular and extravasated neutrophils was determined with a point-counting morphometric method using a square test grid with 8.7-mm spacing.35 Analysis was performed by an operator unaware of the different experimental groups. The density of immunogold (number of gold particles per µm2) was calculated and expressed for each cell compartment. Values are reported as mean ±SEM of n number of the electron micrographs.
Statistical differences between means were determined by analysis of variance followed, if significant, by the Bonferroni test.39 A probability value less than 0.05 was taken as significant.
| Results |
|---|
|
|
|---|
Exogenous and endogenous ANX-A1 down-regulate neutrophil
extravasation in several models of acute
inflammation.6,7,17,22
Initially, we tested the
susceptibility of carrageenin-induced neutrophil migration to the
inhibitory action of ANX-A1. Administration (intravenously) of the
protein produced a dose-related reduction in the number of neutrophils
recovered from the peritoneal cavities at the 4-hour time-point (Figure 1a)
. This effect was mirrored by a
similar reduction in extravasated neutrophils as counted in the
mesenteric tissues (Figure 1a)
.
|
ANX-A1 Expression in Neutrophils Adherent to or Migrated through the Postcapillary Endothelium
The anti-ANX-A1 sera were initially validated by
immunofluorescence. Figure 2a
gives a
histological view of the inflamed mesentery as seen 4 hours after
carrageenin with the presence of intravascular and extravascular
neutrophils. Neutrophils adherent to the postcapillary endothelium were
positive for ANX-A1 (Figure 2b)
. Similarly, neutrophils extravasated
across the postcapillary venules were also positive for the protein. As
control for the primary antibodies nonimmune sheep serum was tested,
but this serum did not give any positive reaction (data not shown).
Similarly, pre-adsorption of LCS3 or LCPS1 with the respective
immunogens (ANX-A1 or peptide Ac2-26) greatly diminished the
immunofluorescent signal (Figure 2
, compare c with d, and e with f).
Together, these data indicated that the LCS3 and LCPS1 sera were
genuinely detecting leukocyte ANX-A1, and encouraged the analysis by
transmission electron microscopy.
|
50%) of LCPS1 immunoreactivity that
detects intact (37 kd) protein was within the membrane compartment,
whereas LCS3 immunoreactivity (that detects both intact and cleaved 33-
kd isoforms) seemed to be more equally distributed throughout the cell
(Table 1)
|
|
|
|
|
Endothelial cells of the postcapillary venules were found to
contain much less ANX-A1 as detected with LCS3. Table 3
reports the quantitative analysis of
ANX-A1 immunoreactivity in endothelial cells, as determined by
immunocytochemistry and quantified in 12 distinct micrographs. A
significant difference between LCPS1 and LCS3 immunoreactivity was seen
between endothelial cells in contact with an intravascular neutrophil
or already passed by a migrated neutrophil. The former antibody
detecting intact 37-kd ANX-A1 in endothelial cells gave modest results
irrespective of the spatial position of the blood-borne leukocyte,
whereas a stronger immunoreactivity was seen with LCS3 once neutrophils
had migrated into the extravascular space (Table 3)
.
|
Positive ANX-A1 mRNA signals were observed in the cytosol of
neutrophils extravasated in the mesenteric tissue of
carrageenin-treated rats (Figure 6, a and d)
. The identity of the cell type was confirmed morphologically by
staining of the same sections with propidium iodide and analysis in the
fluorescence microscope (Figure 6
; a, b, and c). Figure 6b
shows the
strict association between ANX-A1 mRNA and the neutrophil nucleus,
using fluorescence with partial light. No signal was seen in inflamed
tissues stained with sense oligonucleotides, used as negative
control for the in situ hybridization reaction (Figure 6e)
.
|
| Discussion |
|---|
|
|
|---|
Human and rodent neutrophils have abundant ANX-A19,34,42-44 . A substantial amount of protein externalization and secretion (>60% of total content) has been observed on adhesion of this cell type to monolayers of endothelial cells in vitro.16 This is an important issue in our understanding of the biology of this protein. Apart from one study that reported a constitutive secretion of ANX-A1 in human semen,45 it is unclear how the protein can exit the cell and be found in the extracellular space. What is evident, though, is that ANX-A1 protein expression is often associated with inflammatory conditions characterized by accumulation of blood-borne neutrophils. This has been observed in the human lung13,14 and also in rodent models of gut inflammation.11 In the latter study, inflamed tissues secreted ANX-A111 and this was strongly associated with presence of neutrophils.12 In the present investigation we could detect a marked increase in mesenteric ANX-A1 expression in relation to neutrophil infiltration into this tissue. This observation, together with the functional data obtained with exogenous administration of ANX-A1, made carrageenin peritonitis a suitable model to determine the ultrastructural localization of ANX-A1 during an on-going process of neutrophil extravasation.
Intravascular neutrophils were found to be positive for ANX-A1,
distributed in the nucleus, the cytoplasm, and in the plasma membrane.
This distribution is generally in line with observations produced in
other cell types. A partial nuclear localization for ANX-A1 has been
reported in endothelial cells46
and also in human
neutrophils.24
The function of nuclear ANX-A1 is presently
obscure, although electron microscopy analysis of rat mesenteries
showed the presence of ANX-A1 in the nucleus of peri-venular mast
cells and macrophages.35
A different pattern of staining
was obtained with the two polyclonal antibodies. LCPS1, raised against
an N-terminus peptide unique to ANX-A1,8,34
gave a
positive signal that was more abundant in the plasma membrane
compartment (
50% in intravascular neutrophils). The LCS3 serum
produced an almost even staining throughout the adherent neutrophil,
with equal amounts among nucleus, cytosol, and plasma membrane.
Therefore, the majority of ANX-A1 present in the plasma membrane of
adherent neutrophils is in the intact isoform (37 kd). This is the
biologically active species of the protein.47,48
The
present in vivo demonstration of the presence of intact
ANX-A1 on the cell surface of adherent neutrophils extends studies
performed with human cells in vitro.16,24
Overall these data support the hypothesis of an autocrine action for
ANX-A1 externalized on the cell surface7
in a model
susceptible to the inhibitory action of the protein.
The mechanism by which ANX-A1 is transported onto the plasma membrane during the process of neutrophil migration in vivo remains partially obscure. ANX-A1 is mainly localized within the gelatinase granules of human neutrophils, as demonstrated by the in vitro co-localization of antibodies raised against human gelatinase and ANX-A1.24 Because gelatinase granules are mobilized onto the cell surface after neutrophil adhesion to the endothelium,25 this process of controlled exocytosis can permit movement into the extracellular space of a protein devoid of signal peptide as ANX-A1.49 In intravascular neutrophils, adherent to the postcapillary venule endothelium, we could demonstrate a good degree of co-localization between intact ANX-A1 and gelatinase. A different profile was obtained in extravasated cells, with a very low degree of gelatinase immunoreactivity indicating that the enzyme was almost entirely exocytosed.25 ANX-A1 follows a different biochemical path, and this is discussed below. From this set of experiments, we can propose that adhesion-dependent neutrophil exocytosis might be responsible for ANX-A1 externalization also in an in vivo experimental condition. It is possible that localization in similar or other subcellular organelles may be responsible for the export of ANX-A1 outside other cell types33,50 including the monocyte.51
A striking difference was observed between the ANX-A1 immunoreactivity produced by the two anti-sera with respect to neutrophils extravasated in the extracellular matrix. The plasma membrane of these cells was significantly less positive for LCPS1 than intravascular adherent neutrophils. An opposite result was obtained with LCS3. Extravascular neutrophils demonstrated the classical signs of cell activation, with membrane ruffles and presence of large vacuoles in the cytosol. ANX-A1 immunoreactivity was particularly accumulated in the latter organelles, probably generated by endocytosis. Relevantly, ANX-A1 association with early but not multivesicular endosomes has been reported in MDCKII cells.52 In our experimental conditions and cells, the immunoreactivity detected by electron microscopy was mainly because of the cleaved (33 kd) ANX-A1 species.
We believe this result is of importance for determining the biochemical pathways that may be operating on ANX-A1 during the process of neutrophil extravasation. In fact, it has long been known that analysis of biological samples for ANX-A1 content often generated a double band when determined by Western blotting analysis, corresponding to the 37- and 33-kd species.12,53 The occurrence of a putative spontaneous ANX-A1 protein degradation has been invoked as responsible for this recurrent feature.47 We have recently proposed the existence of a specific enzymatic activity (termed lipocortinase) responsible for cleavage of intact ANX-A1 and removal of a portion of the N-terminus,7,16 selectively activated during the process of neutrophil activation. Such an activity will be responsible for the appearance of the cleaved (33 kd) isoform in inflammatory samples, as seen in the bronchoalveolar lavage of patients suffering from different forms of lung inflammatory disorders13 or in the gut of rats affected by colitis.12 A recent study by Tsao and colleagues14 has sequenced the exact cleavage site in human ANX-A1 recovered in the bronchoalveolar lavage fluid of patients affected by cystic fibrosis, proposing a causal role for neutrophil elastase. A different site of cleavage has been proposed by a distinct study performed with reconstitute neutrophil granules in vitro.54 In addition, it is also possible that ANX-A1 phosphorylation may change the susceptibility of the protein to proteolysis.55
Our data demonstrate for the first time the occurrence of ANX-A1
cleavage at the ultrastructural level monitoring neutrophils in the
process of interacting, or a few hours after the interaction, with the
postcapillary venule endothelium. Intravascular neutrophils adherent to
the endothelium have the majority of cell surface ANX-A1 present in the
intact form, whereas extravasated cells have the majority of
cell-associated ANX-A1 in the cleaved isoform, localized in large
endosome-like vacuoles. We suggest that the immunoreactivity detected
with LCS3 in the vacuoles of extravasated neutrophils is because of the
internalized cleaved ANX-A1, which was intact and on the cell surface
at the step of neutrophil adhesion. Figure 7
schematizes this working hypothesis
that, in our opinion, is the most likely to explain the data obtained
by this immunocytochemical investigation.
|
Finally, in situ hybridization of flat-mount mesenteric preparations detected ANX-A1 mRNA in extravasated neutrophils. This is the first positive in situ hybridization data obtained for ANX-A1 in these cells, and in a way it is not surprising because of the strong positive signal for ANX-A1 protein displayed by inflamed tissues.11 Neutrophil passage though monolayers of endothelial cells in vitro does not activate ANX-A1 synthesis.16 It is therefore likely that neutrophil interaction with the extracellular matrix signals for activation of the gene. In addition, ANX-A1 gene is under control of specific transcription factors, such as nuclear factor interleukin-6 or C/EBP-{beta} in the mouse,57,58 and the cytokine interleukin-6 present during the early phases of carrageenin inflammation.59 Future studies will address the mechanisms responsible for ANX-A1 gene activation in extravasated neutrophils. What is important, at this stage, is the observation that cell extravasation leads to the activation of genes for pro-inflammatory cytokines (eg, tumor necrosis factor60 ) as well as for anti-inflammatory mediators such as ANX-A1.
An interesting comparison can be made among the different mediators
that fall in the group of anti-inflammatory agonists.7
With respect to neutrophil adhesion to monolayers of endothelial cells,
the ANX-A1 derived N-terminal peptide Ac2-26 produces
60%
inhibition at 11 µmol/L,61
with lipoxin
A4 and aspirin-triggered lipoxin
A4 producing >50% reduction at 5 µmol/L
concentration.62
Full-length ANX-A1 inhibits shedding of
L-selectin from the cell surface of activated neutrophils
by a third (to
60% of control L-selectin levels) at 3
µg/ml corresponding to 80 nmol/L,63
whereas
aspirin-triggered lipoxin A4 produced a similar
effect at 50 nmol/L.62
Native lipoxin
A4 is almost 10-fold less potent in this
assay.62
In vivo the comparison is more
favorable to ANX-A1, likely for pharmacokinetics reasons. Almost 80%
inhibition of cytokine-induced neutrophil migration into a murine
dorsal air-pouch was achieved with 10 µg of ANX-A1 per mouse
(corresponding to 2 nmol),17
200 µg of peptide Ac2-26
(corresponding to 65 nmol per mouse),48
or by 10 µg of
15-epi-16-phenoxy-lipoxin A4 (
200
nmol).64
In conclusion, this study has used an immunocytochemical approach to study the alterations in the ANX-A1 biochemical pathways during an on-going process of neutrophil extravasation in vivo. The major indication is that both ANX-A1 protein and mRNA undergo changes in their content and localization when neutrophils adhere to the endothelium of postcapillary venules or immediately after this, when blood-borne cells are in contact with the extracellular matrix. These observations will shed light on the intimate mechanisms regulating the functions of this important protein in the biology of the neutrophilic polymorphonuclear leukocyte.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by the Arthritis Research Campaign United Kingdom (grant P0567). R. J. F. is a principal fellow of the Wellcome Trust, and M. P. is a post-doctoral fellow of the Arthritis Research Campaign. S. M. O. was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil.
Accepted for publication October 20, 2000.
| References |
|---|
|
|
|---|
in endotoxin-challenged lung tissue. Am J Pathol 1993, 143:1009-1015[Abstract]
This article has been cited by other articles:
![]() |
T. S. Gastardelo, A. S. Damazo, J. Dalli, R. J. Flower, M. Perretti, and S. M. Oliani Functional and Ultrastructural Analysis of Annexin A1 and Its Receptor in Extravasating Neutrophils during Acute Inflammation Am. J. Pathol., January 1, 2009; 174(1): 177 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. K. Lim and S. Pervaiz Annexin 1: the new face of an old molecule FASEB J, April 1, 2007; 21(4): 968 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D'Acquisto, A. Merghani, E. Lecona, G. Rosignoli, K. Raza, C. D. Buckley, R. J. Flower, and M. Perretti Annexin-1 modulates T-cell activation and differentiation Blood, February 1, 2007; 109(3): 1095 - 1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Babbin, W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat Annexin I Regulates SKCO-15 Cell Invasion by Signaling through Formyl Peptide Receptors J. Biol. Chem., July 14, 2006; 281(28): 19588 - 19599. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Damazo, S. Yona, R. J. Flower, M. Perretti, and S. M. Oliani Spatial and Temporal Profiles for Anti-Inflammatory Gene Expression in Leukocytes during a Resolving Model of Peritonitis J. Immunol., April 1, 2006; 176(7): 4410 - 4418. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perretti and R. J. Flower Annexin 1 and the biology of the neutrophil J. Leukoc. Biol., July 1, 2004; 76(1): 25 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ernst, C. Lange, A. Wilbers, V. Goebeler, V. Gerke, and U. Rescher An Annexin 1 N-Terminal Peptide Activates Leukocytes by Triggering Different Members of the Formyl Peptide Receptor Family J. Immunol., June 15, 2004; 172(12): 7669 - 7676. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. La, T. V. Cao, G. Cerchiaro, K. Chilton, J. Hirabayashi, K.-i. Kasai, S. M. Oliani, Y. Chernajovsky, and M. Perretti A Novel Biological Activity for Galectin-1: Inhibition of Leukocyte-Endothelial Cell Interactions in Experimental Inflammation Am. J. Pathol., October 1, 2003; 163(4): 1505 - 1515. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perretti and F. N. E. Gavins Annexin 1: An Endogenous Anti-Inflammatory Protein Physiology, April 1, 2003; 18(2): 60 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perretti, F. Ingegnoli, S. K. Wheller, M. C. Blades, E. Solito, and C. Pitzalis Annexin 1 Modulates Monocyte-Endothelial Cell Interaction In Vitro and Cell Migration In Vivo in the Human SCID Mouse Transplantation Model J. Immunol., August 15, 2002; 169(4): 2085 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. LA, M. D'AMICO, S. BANDIERA, C. DI FILIPPO, S. M. OLIANI, F. N. E. GAVINS, R. J. FLOWER, and M. PERRETTI Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action FASEB J, October 1, 2001; 15(12): 2247 - 2256. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |